| Project Detail |
Efficient therapeutic delivery across the blood-brain barrier (BBB) remains a significant challenge in treating neurological disorders. The BBB, composed of tightly regulated endothelial cells, severely restricts drug access to the brain, reducing efficacy and increasing off-target effects. While lipid nanoparticles (LNPs) have been essential for developing mRNA-based vaccines, their use in brain-targeted therapies is limited by poor BBB penetration and suboptimal mRNA translation. Apolipoproteins, our body’s own nanodelivery system, possess the inherent ability to cross the BBB. Extensive preliminary data demonstrate that apolipoprotein nanoparticles (aNPs) efficiently integrate mRNA for extrahepatic delivery and are a compelling platform for brain targeting. While mRNA immune cell delivery firmly established, I propose exploring apolipoprotein nanoparticles (aNPs) for mRNA delivery to the brain. The PORTAL project aims to harness the unique properties of apolipoproteins to deliver mRNA across the BBB. By screening 400 compositionally diverse aNPs—comprising apolipoprotein A1, E, and fusion apolipoproteins targeting BBB receptors—this project seeks to identify lead candidates for effective mRNA delivery to the brain. Each aNP will carry mRNA encoding Cre recombinase, along with unique DNA barcodes for detailed biodistribution and functional studies in the A14 neuroinflammation mouse model. By integrating protein engineering, RNA therapeutics, and preclinical neuroinflammation models, this research aims to uncover key factors driving BBB penetration and mRNA delivery efficiency. The innovative combination of apolipoproteins and lipid nanotechnology will unlock new pathways to the brain, setting a new standard for RNA-based treatments. Upon completion of this Program, I will be equipped with cutting-edge technical, teaching, and leadership skills, empowering me to excel as an independent researcher and drive innovation of nanomedicine brain treatments. |
